First-pass extracted concept

lymphotoxin-beta receptor

Candidate: concept label1 source documents5 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

LTβR

Evidence Snippets

The lymphotoxin-beta receptor (LTβR), a member of the tumor necrosis factor (TNF) receptor superfamily, is broadly expressed on stromal, endothelial, and myeloid cells within the TME and signals through both canonical and non-canonical NF-κB pathways.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 5 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1combination strategysupports2026Source 1DOI PubMed

Selective LTβR modulation may synergize with immune checkpoint blockade and CAR T cell therapies to overcome immunotherapy resistance in refractory solid tumors.

Claim 2disease context effectsupports2026Source 1DOI PubMed

Persistent LTβR signaling supports immunosuppressive macrophage phenotypes and promotes tumor growth in hepatocellular carcinoma.

Claim 3functional dualitysupports2026Source 1DOI PubMed

Depending on context and activation mode, LTβR can drive either tumor progression or anti-tumor immunity.

Claim 4mechanismsupports2026Source 1DOI PubMed

LTβR signals through both canonical and non-canonical NF-κB pathways.

Claim 5preclinical effectsupports2026Source 1DOI PubMed

In preclinical colorectal and cervical cancer models, LTβR activation induces tertiary lymphoid structures, high endothelial venules, and immune infiltration, improving responsiveness to immune checkpoint blockade.